1. KEYNOTE-867: pembrolizumab adds toxicity without improving outcomes after lung SBRT
In 448 patients with unresected early-stage NSCLC, adding pembrolizumab to SBRT did not improve event-free survival (HR 0.92). Grade 3–5 treatment-related toxicity increased from 3.7% to 20.4%, with five treatment-related deaths in the pembrolizumab group.
2. ASTRO 2026 recommends moderate hypofractionation across all prostate cancer risk groups
Updated ASTRO guidance recommends moderate hypofractionation for all localized prostate cancer risk groups, supports five-fraction SBRT in low- and intermediate-risk disease, and restricts ultrahypofractionated elective pelvic nodal irradiation to clinical trials.
3. SwallPEG finds no significant swallowing difference between gastrostomy strategies
In a randomized phase III trial, prophylactic PEG did not significantly improve six-month swallowing quality of life versus reactive placement (MDADI 69.5 vs 74.7). Early closure after 57 eligible patients limits conclusions about equivalence.
4. Lenalidomide–dexamethasone plus RT linked to longer disease control in solitary plasmacytoma
Ten-year progression-free survival was 71.8% with RT plus lenalidomide–dexamethasone versus 26.7% with RT alone. The 75-patient comparison was nonrandomized, and multiple myeloma-free survival was not significantly improved.
5. Metastasis-directed therapy linked to better control in metastatic nasopharyngeal cancer
Among 54 patients receiving definitive locoregional RT, two-year recurrence-free survival was 81.9% with metastasis-directed therapy versus 28.2% without. Major differences in metastatic burden and treatment selection limit causal interpretation.
That's the week. See you next Sunday.